Riverside Partners has promoted Michelle Noon and Max Osofsky to partner. The company has also promoted Craig Stern to principal. Prior to joining Riverside, Noon worked at Thoma Bravo and Morgan Stanley while Osofsky was at Summit Partners where he served as a vice president. And before joining Riverside, Stern was at Nextag where he worked as a vice president of corporate development.
January 7, 2015
Riverside Partners, a Boston-based private equity firm with $1 billion in assets under management, focused on middle market healthcare and technology companies, is pleased to announce the promotions of Michelle Noon and Max Osofsky to Partner as well as the promotion of Craig Stern to Principal. The promotions further strengthen the firm’s investment team as they continue to invest the firm’s most recent fund, Riverside Fund V, L.P., a $561 million equity fund.
“We are very proud of the team that we are building at Riverside Partners and we are thrilled to be developing partners from within our organization,” said David Belluck, General Partner. “Since joining the firm over six years ago, both Michelle and Max have demonstrated the dedication, investment expertise, and values that are important to our partnership. We expect both of them to continue to be key contributors and leaders of the firm. And we are also excited to promote Craig Stern to Principal, as he has been instrumental in completing several healthcare and healthcare IT investments since joining Riverside.”
Michelle Noon joined Riverside Partners in 2008 and focuses on technology investments. She brings more than 12 years of experience in private equity and finance to her role. Michelle has added significant value to Riverside’s portfolio companies including board roles on Thinklogical, Pilgrim Quality Solutions and GEMCITY Engineering. Prior to joining Riverside, Michelle focused on software and business services investments at Thoma Bravo (fka Thoma Cressey Equity Partners) in San Francisco. Michelle also worked as part of the investment banking group of Morgan Stanley in New York where she focused on the energy and utilities industries. Michelle holds a bachelor in business administration in finance and business economics, magna cum laude, from the University of Notre Dame and a Master of Business Administration with distinction from the Harvard Business School.
Max Osofsky brings more than 14 years of consulting and private equity experience to the Riverside Partners’ team, which he joined in 2008. Max focuses on investments in the healthcare sector. He was a part of the team that successfully acquired a stake in Vocollect, which was sold to Intermec (now Honeywell) in 2011. Max currently plays a key role with several Riverside portfolio companies, including Allied Dental, Dominion Diagnostics, Tegra Medical and HealthDrive. Prior to joining Riverside, Max was a Vice President at Summit Partners, and a consultant at Bain & Company. He holds a Bachelor of Science in Economics, summa cum laude, from The Wharton School of the University of Pennsylvania, and a Master of Business Administration from Harvard Business School.
Craig Stern joined Riverside Partners in 2012 and brings more than 13 years of private equity and operations experience to the firm. Craig focuses on investments in the healthcare sector. He works closely with several Riverside portfolio companies and serves as a board director of Enovate Medical and BioAgilytix Labs. Prior to joining Riverside, Craig was Vice President, Corporate Development at Nextag, Inc., a technology and e-commerce company, where he was responsible for acquisitions. Before joining Nextag, Craig was a Vice President at Providence Equity Partners and an investment professional at General Atlantic Partners. Prior to that, Craig worked in the telecommunications group within the investment banking division of Morgan Stanley. Craig holds a Bachelor of Arts degree in Economics and East Asian Studies, with honors, from Harvard College and a Master of Business Administration from Harvard Business School.
About Riverside Partners
Founded in 1989, Riverside Partners is a middle market private equity firm currently investing Riverside Fund V, L.P. The fund focuses on growth-oriented companies primarily in the healthcare and technology industries. Riverside Partners is particularly experienced at partnering with founders, owners and management teams and it brings substantial domain expertise and operating experience to its portfolio companies. Today, Riverside Partners manages $1 billion of equity capital and seeks to make investments in companies with revenues between $20 and $200 million and with $5-$25 million of EBITDA.